Literature DB >> 3928061

Antagonism of ceftazidime by chloramphenicol in vitro and in vivo during treatment of gram negative meningitis.

G L French, T K Ling, D P Davies, D T Leung.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3928061      PMCID: PMC1417488          DOI: 10.1136/bmj.291.6496.636

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


× No keyword cloud information.
  3 in total

1.  Treatment of pneumococcic meningitis with penicillin compared with penicillin plus aureomycin; studies including observations on an apparent antagonism between penicillin and aureomycin.

Authors:  M H LEPPER; H F DOWLING
Journal:  AMA Arch Intern Med       Date:  1951-10

2.  Studies on antibiotic synergism and antagonism; the interference of chloramphenicol with the action of penicillin.

Authors:  E JAWETZ; J B GUNNISON; R S SPECK; V R COLEMAN
Journal:  AMA Arch Intern Med       Date:  1951-03

3.  Chloramphenicol inhibition of the bactericidal effect of ampicillin against Haemophilus influenzae.

Authors:  V Rocco; G Overturf
Journal:  Antimicrob Agents Chemother       Date:  1982-02       Impact factor: 5.191

  3 in total
  4 in total

Review 1.  Suppressive drug combinations and their potential to combat antibiotic resistance.

Authors:  Nina Singh; Pamela J Yeh
Journal:  J Antibiot (Tokyo)       Date:  2017-09-06       Impact factor: 2.649

Review 2.  Ceftazidime. An update of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  C P Rains; H M Bryson; D H Peters
Journal:  Drugs       Date:  1995-04       Impact factor: 9.546

3.  Hidden suppressive interactions are common in higher-order drug combinations.

Authors:  Natalie Ann Lozano-Huntelman; April Zhou; Elif Tekin; Mauricio Cruz-Loya; Bjørn Østman; Sada Boyd; Van M Savage; Pamela Yeh
Journal:  iScience       Date:  2021-03-26

Review 4.  An alternate pathophysiologic paradigm of sepsis and septic shock: implications for optimizing antimicrobial therapy.

Authors:  Anand Kumar
Journal:  Virulence       Date:  2013-11-01       Impact factor: 5.882

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.